Plaintiff(s) v. Defendant(s)

Track this case

Case overview

Case Number:

1:99-mc-09999

Court:

Delaware

Nature of Suit:

Other Statutory Actions

Judge:

Unassigned Judge

  1. February 07, 2018

    FDA Approves Gilead's HIV Med; Rival Claims Infringement

    Hours after the U.S. Food and Drug Administration approved Gilead Sciences Inc.'s new HIV medication Biktarvy, rival ViiV Healthcare Co. filed a patent infringement lawsuit in Delaware federal court Wednesday accusing the biotech company of copying its Tivicay drug, which in 2016 hit $1.4 billion in sales.

  2. February 12, 2016

    Navient Hid Compliance Failures From Investors, Suit Says

    Navient Corp. misled investors to believe that its loan services complied with federal regulations, causing shares to fall after the Consumer Financial Protection Bureau and Hillary Clinton raised red flags, a proposed investor class has alleged in Delaware federal court.

  3. December 21, 2015

    Toyota, BMW, Others Targeted Over Infotainment Patents

    Advanced Silicon Technologies LLC launched a number of suits Monday against Toyota, BMW, Volkswagen and other automotive companies and suppliers for allegedly infringing its infotainment system patents.

  4. August 03, 2015

    Lupin's Generic Colitis Drug Infringes Patents, Pharmas Say

    Cosmo Technologies Ltd. and a Salix Pharmaceuticals Ltd. subsidiary sued in Delaware federal court Friday to block Lupin Ltd.'s abbreviated new drug application for a generic version of the colitis treatment Uceris.

  5. August 21, 2014

    DuPont Slaps SunEdison With Solar Paste Patent Suit

    DuPont Co. slapped solar technology company SunEdison Inc. and its subsidiary NVT LLC with an infringement suit in Delaware federal court on Monday, alleging they are infringing on its thick-film paste patent by importing and selling certain solar modules.

  6. May 08, 2014

    First Eagle Overcharged Funds With Advisory Fees, Suit Says

    Two investment trusts sued First Eagle Investment Management Wednesday in Delaware federal court on behalf of two of its funds, alleging that the $400 million the asset manager charged the funds in advisory fees last year is "disproportionately large."